University of Thessaly (UTH)
Επίδραση ενός GnRH ανταγωνιστή στην έκκριση της LH φυσιολογικών γυναικών
Abstract
dc:descriptionGanirelix is a GnRH antagonist, which is widely used in Assisted Reproduction Technology (ART), for the prevention of premature LH peaks. Kisspeptin is a neuropeptide, which is secreted from the hypothalamus, and may have a crucial role on the onset of puberty in humans and on ovulation in women. The aim of this study was to examine the effect of Ganirelix on the secretion of LH and on follicle maturation in healthy women. Patients and measurements: Ten healthy female volunteers were studied during two menstrual cycles, i.e. cycle 1 (control, spontaneous cycle) and cycle 2 (Ganirelix). In both cycles, blood samples were taken daily starting on cycle day 2 until ovulation occurred on cycle 1 and transvaginal ultrasound was performed on cycle day 8 and 10 and then on a daily basis until ovulation occurred. During cycle 2, all women were given S.C. injections of the GnRH antagonist Ganirelix at the dose of 0,25 mg/day, starting on cycle day 2 until the day of the endogenous LH surge in cycle 1. In all blood samples, FSH, LH, Estradiol, Progesterone and Kisspeptin levels were measured. Results: During treatment with Ganirelix FSH levels remained stable and similar to those in cycle 1. LH levels were reduced in cycle 2 as compared to cycle 1 on days 3, 4, 7 and 9 (P<0,05), with no significant within-cycle variation. Estradiol levels until day 10 did not differ significantly between the two cycles. After day 10, no follicle maturation and no substantial increase in serum estradiol levels were observed in the antagonist cycle (cycle 2), in contrast to cycle 1. In cycle 1, ovulation was observed in 9 women. In cycle 2, one volunteer ovulated, despite the treatment with Ganirelix, and in 8 women ovulation was postponed for a week. Serum Kisspeptin levels were similar in both cycles, except on days 5 and 6 (P<0,05) in which they were higher in cycle 2. There was no significant within-cycle variation in Kisspeptin levels during the follicular phase. No correlation was found between serum FSH, estradiol and progesterone levels and those of Kisspeptin. However, Kisspeptin levels showed a positive correlation with those of LH on cycle days 2 (r=0,89, Ρ<0,01) and 3 (r=0,79, Ρ<0,05). Conclusions: This study shows for the first time that Ganirelix interferes with the selection of the dominant follicle. Since circulating gonadotrophin levels did not change substantially, it is suggested that Ganirelix affects the process of follicle selection by acting on the ovary. This, however, needs to be further investigated. Regarding the role of Kisspeptin in Ganirelix-suppressed gonadotrophin secretion further studies are required.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pousias, Serafeim
- Πούσιας, Σεραφείμ
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46215